NCT05130177 - Zimberelimab (AB122) With TIGIT Inhibitor Domvanalimab (AB154) in PD-1 Relapsed/Refractory Melanoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 16, 2022

Primary Completion Date

January 31, 2028

Study Completion Date

January 31, 2031

Conditions

Melanoma

Interventions

DRUG

Zimberelimab

Zimberelimab is a fully human immunoglobulin G4 (hIgG4) monoclonal antibody (mAb) that targets the human programmed cell death-1 (PD-1) immune checkpoint.

DRUG

Domvanalimab

Domvanalimab is a humanized immunoglobulin G1 (IgG1) mAb that targets immune checkpoint TIGIT.

Trial Locations (1)

15232

RECRUITING

UPMC Hillman Cancer Center, Pittsburgh